⌘K
t
| TIDM | HEMO |
| Share Price | GBX 775.00-3.87% |
| Market Cap | £49.80m |
Hemogenyx Pharmaceuticals plc shareholders passed all eight resolutions at the Annual General Meeting held on May 29, 2025. Resolution 1 (annual accounts) passed with 97.31% of votes cast, and Resolution 3 (re-appointment of Peter Redmond as director) passed with 75.44% of votes cast. The total votes cast for the resolutions ranged from 17.40% to 18.37% of the Company's issued share capital of 4,343,539 ordinary shares.
| Date | 29 May 2025 |
| Time | 14:06:16 |
| Category | AGMs and other meetings |
| ID | 6553K |
29 May 2025
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Annual General Meeting
Hemogenyx Pharmaceuticals plc is pleased to announce that, at the Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed by shareholders. The numbers of proxy votes for each resolution submitted prior to the meeting are presented below.
Proxy Voting Results
|
Ordinary Resolutions |
Votes for |
% of votes cast for |
Votes Against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
1. To receive and adopt the Company's annual accounts for the financial year ended 31 December 2024 together with the directors' reports and auditor's report on those accounts |
769,396 |
97.31 |
21,278 |
2.69 |
790,674 |
18.20 |
12,514 |
|
2. To approve the Directors' Remuneration Report |
621,455 |
78.62 |
168,962 |
21.38 |
790,417 |
18.20 |
12,771 |
|
3. To authorise the re-appointment of Peter Redmond |
601,846 |
75.44 |
195,969 |
24.56 |
797,815 |
18.37 |
5,373 |
|
4. To re-appoint PKF Littlejohn LLP as auditors |
729,108 |
95.29 |
36,001 |
4.71 |
765,109 |
17.61 |
38,079 |
|
5. To authorise the Audit Committee to determine the level of the auditor's remuneration |
647,389 |
85.67 |
108,250 |
14.33 |
755,639 |
17.40 |
47,549 |
|
6. To grant the Directors authority to allot and issue shares and grant rights to subscribe for shares in the Company for the purposes of Section 551 of the Act. |
639,852 |
81.03 |
149,808 |
18.97 |
789,660 |
18.18 |
13,528 |
|
Special Resolutions |
Votes for |
% of votes cast for |
Votes against |
% of votes cast against |
Total votes cast |
Total votes cast as % of ISC (1) |
Votes with-held (2) |
|
7. To dis-apply the statutory rights of pre-emption in respect of the allotment of equity securities for cash under Section 561(1) of the Act. |
638,646 |
80.88 |
151,014 |
19.12 |
789,660 |
18.18 |
13,528 |
|
8. To authorise the Directors to call a general meeting of the Company, other than an annual general meeting, |
763,850 |
96.72 |
25,924 |
3.28 |
789,774 |
18.18 |
13,414 |
(1) The Company's issued share capital ("ISC") on 27 May 2025, being the date on which members had to be entered in the register of members of the Company in order to be entitled to attend and vote at the meeting, was 4,343,539 ordinary shares.
(2) A 'vote withheld' in respect of any resolution is not a vote in law and is not counted in the calculation of the proportion of the votes for and against it.
A copy of the resolutions passed has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
|
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl |
|
|
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.